Big Pharma, VCs Bet $105M on Mediar’s Antibodies for Fibrotic Diseases

Fibrosis has been a tough field for biomedical R&D. The liver, the lungs, and the kidneys are all organs where inflammation and tissue scarring can add up over time, causing a lot of misery.

Today, a syndicate of pharma companies and venture capitalists are wagering on a new biological strategy for treatment.

Access the article on (paywall)